AARS1

Chr 16ADAR

alanyl-tRNA synthetase 1

Also known as: AARS, CMT2N, DEE29, EIEE29, HDLS2, TTD8

The human alanyl-tRNA synthetase (AARS) belongs to a family of tRNA synthases, of the class II enzymes. Class II tRNA synthases evolved early in evolution and are highly conserved. This is reflected by the fact that 498 of the 968-residue polypeptide human AARS shares 41% identity witht the E.coli protein. tRNA synthases are the enzymes that interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. They consist of a catalytic domain which interacts with the amino acid acceptor-T psi C helix of the tRNA, and a second domain which interacts with the rest of the tRNA structure. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismAD/ARLOEUF 0.624 OMIM phenotypes
Clinical SummaryAARS1
🧬
Gene-Disease Validity (ClinGen)
Charcot-Marie-Tooth disease axonal type 2N · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

3 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
93 unique Pathogenic / Likely Pathogenic· 840 VUS of 1700 total submissions
📖
GeneReview available — AARS1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.62LOEUF
pLI 0.000
Z-score 3.75
OE 0.43 (0.310.62)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.05Z-score
OE missense 0.99 (0.931.07)
538 obs / 541.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.43 (0.310.62)
00.351.4
Missense OE?0.99 (0.931.07)
00.61.4
Synonymous OE?1.08
01.21.6
LoF obs/exp: 22 / 50.9Missense obs/exp: 538 / 541.4Syn Z: -0.96
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongAARS1-related early-onset epileptic encephalopathy with persistent myelination defectLOFAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.6649th %ile
GOF
0.6248th %ile
LOF
0.3358th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Literature Evidence

DNThis suggests that neuropathy-associated AARS1 variants exert a dominant-negative effect, which supports a common, loss-of-function mechanism for ARS-mediated dominant peripheral neuropathy.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 37010095

ClinVar Variant Classifications

1700 submitted variants in ClinVar

Classification Summary

Pathogenic58
Likely Pathogenic35
VUS840
Likely Benign620
Benign44
Conflicting81
58
Pathogenic
35
Likely Pathogenic
840
VUS
620
Likely Benign
44
Benign
81
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
45
4
9
0
58
Likely Pathogenic
22
11
2
0
35
VUS
16
752
63
9
840
Likely Benign
1
21
275
323
620
Benign
0
2
39
3
44
Conflicting
81
Total847903883351,678

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

25 pathogenic / likely-pathogenic (of 52) ClinVar copy-number / structural variants overlap AARS1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

AARS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →